Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.32

-1.7%

12:25 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3967)	6/3/2001 9:28:46 AM
From: Biotech Jim	Read Replies (2) of 52153

Abarelix weaknesses may include the monthly injections, loss of masculine secondary sex characteristics (not a big deal if androgen-dependant cancer is to be eliminated) and the lack of much published literature on its activities. Others are working on nonpeptide GNRH antagonists. A look at issued US patents shows that Merck has an extensive effort with over 20 issued patents, M. Goulet appears to be heading this effort. In my limited analysis, MRK does not seem to have made any announcements here, but this is not unusual for them especially after the MK 869 fiasco. I would put a significant bet that they are easily in the lead here. Agouron and of course NBIX have limited efforts here as well. S. Sealfon at Mount Sinai holds a receptor patent. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next